Keymed Biosciences Announces Approval Of Stapokibart For The Treatment Of Chronic Rhinosinusitis With Nasal Polyposis ...Middle East

CHENGDU, China, Dec. 23, 2024 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") of China has recently approved the supplemental New Drug Application (the "sNDA") of Stapokibart (anti-IL-4Rα monoclonal antibody,...

Read More Details
Finally We wish PressBee provided you with enough information of ( Keymed Biosciences Announces Approval Of Stapokibart For The Treatment Of Chronic Rhinosinusitis With Nasal Polyposis )

Also on site :

• European militarization robbing taxpayers – Lavrov
• 'Golden Bachelor' Mel Owens Issues Bold Statement About Upcoming Season
• Tobey Maguire's 'Spider-Man' Trilogy Returns to Theaters With Rare Extended Cut